EGFR and neoplasm: In summary, we demonstrate that ABT-869 and chemotherapies act synergistically to inhibit the tumor growth and angiogenesis in vitro and in vivo through simultaneous blockade of EGFR-, IGF1R- and VEGR2-mediated AKT/mTOR signaling pathways.